Physician profile
Paul S Riske
NPI 1649477860
$2,036.41
in general payments reported to CMS, 2019-2025
16 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $144 · 2021: $310 · 2022: $313 · 2023: $339 · 2024: $162 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $701.70 | 2019-2025 | Clareon Panoptix Pro |
| Abbvie INC. | $406.24 | 2023-2025 | Botox |
| Horizon Therapeutics Plc | $195.64 | 2020-2023 | Tepezza |
| Merz North America, INC. | $150.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $116.63 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $106.47 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $86.61 | 2019-2021 | |
| Amgen INC. | $66.82 | 2024-2025 | Tepezza |
| Merz Pharmaceuticals, LLC | $54.44 | 2021-2022 | |
| Allergan, INC. | $38.06 | 2020 | |
| Eyevance Pharmaceuticals LLC | $29.96 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb Americas INC. | $18.68 | 2023 | Vyzulta |
| Shire North American Group INC | $17.88 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.93 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Riske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.